

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog	Status
Amoxicillin/clavulanate 500mg/125mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion	Ineligible for inclusion	No	No
Bedaquiline 20mg tablet	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes
Bedaquiline 100mg tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Yes	Yes	Yes
Clofazimine 50mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Cycloserine 125mg capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Delamanid 25mg dispersible tablet	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	No	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog	Status
Delamanid 50mg dispersible tablet	Yes	Yes	No	No	Yes	No	No	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Delamanid 50mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	Yes
Ethambutol 50mg dispersible tablet	Yes	Yes	No	No	No	N/A	Yes	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Ethambutol 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	Yes	Yes
Ethionamide 125mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 50mg dispersible tablet	Yes	Yes	No	No	No	Ineligible for inclusion	Yes	Yes	No	Ineligible for inclusion	No	No

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog	Status
Isoniazid 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	No
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Levofloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Linezolid 20mg/mL oral suspension	Yes	Yes	Yes	Removed	Yes	No	No	No	No	Ineligible for inclusion	No	No
Linezolid 150mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Linezolid 600mg tablet	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog	Status
Meropenem 500mg vial	Yes	Yes	Yes	Yes	No	Ineligible for inclusion	Ineligible for inclusion	No	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Meropenem 1000mg vial	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Meropenem/clavulanate 1000 mg/125 mg vial	Yes	Yes	No	No	Yes	No	No	Ineligible for inclusion	No	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
Moxifloxacin 100mg dispersible tablet	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Moxifloxacin 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
PAS 4gm granules	Yes	Yes	Yes	Removed	Yes	No	No	Yes	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion	Ineligible for inclusion
PAS Sodium 4gm/5.52gm powder	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion

DR-TB: Drug-Resistant TB
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: February 2024

Pediatric Drug-Resistant TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](#).

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2024)	Global Fund ERP recommended	GDF Catalog	Status
Pyrazinamide 150mg dispersible tablet												Yes

DR-TB: Drug-Resistant TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2024